Background: The combination of ledipasvir plus sofosbuvir was recently approved
| INTRODUCTION
In 2008, Egypt had the highest worldwide HCV prevalence at around 14%.
1 Since then, this burden has significantly decreased (by around 30% in 2015) in adult patients, after the introduction of Interferon and ribavirin in the standard of care. 1 The major burden of HCV is progression to advanced liver disease and to hepatocellular carcinoma (HCC).
Unfortunately, the estimated HCV seroprevalence rate in Egypt in children and adolescents is approximately 6%, which is considered high. 2 In most children, the clinical presentation is subtle or associated with mild manifestations. 3 In a minority of children, the disease progresses to develop significant fibrosis and liver cirrhosis. 4 Spontaneous resolution occurs in children aged 7-8. 5 Infected adolescents follow the same clinical adult disease pattern 6 with a 26-fold increased risk of CLDassociated mortality, 7 and HCC development in the absence of cirrhosis and increased requirement of liver transplantation. 8 Eradication of HCV in paediatric and adolescent patients is equally important as in adult patients to avoid disease progression and subsequent HCC. 8 The current available treatment options in that group of patients are very limited. 9 One accepted option has been the combination of pegylated interferon a and ribavirin, although the latter regimen has a limited efficacy (<30%) in genotype 4. [10] [11] [12] In addition, treatment discontinuation has also been required due to the serious adverse effects associated with this regimen. [10] [11] [12] [13] The launch of the national programme for treatment of HCV in Egypt led to the introduction of direct-acting
anti-viral drugs with lower prices, and allowed the treatment of many patients (exceeding one million adults) with SVR above 96% and with a high safety profile. 13, 14 Currently, the Food and Drug Administration (FDA) has expanded the use of ledipasvir plus sofosbuvir for the treatment of HCV in children and adolescents aged ≥12 or weighing ≥35 kg, without cirrhosis or with compensated cirrhosis. 15 The 
| Routine laboratory assessment
Routine laboratory tests including complete blood picture (haemoglobin, total leucocyte count, platelets), international normalisation ratio Only measurements with at least ten valid acquisitions, a success rate >60%, and an interquartile range (IQR/M) <30% were included in the study. Staging of liver fibrosis was assessed as suggested by multicentre analysis studies: no significant fibrosis: F0/F1 <7.1 kPa, significant fibrosis ≥F2 = 7.1-9.9 kPa; advanced fibrosis F3 ≥10-13 kPa: liver cirrhosis F4 ≥13 kPa. 
| Transient elastography

| Monitoring of treatment safety
Treatment safety was monitored using biochemical and haematological parameters during treatment at week 4 (W4), week 8 (W8), week 12 (EOT) and 12 weeks after the end of treatment (SVR12).
Clinical monitoring was also performed at the same visits, with adverse effects (serious and simple) being recorded for every patient. Serious adverse events were defined as events (laboratory or clinical) that interfered with treatment proceeding, including death.
| Statistical analysis
Continuous variables were summarised by means, standard deviations, and minimum and maximum variables. Categorical variables were summarised by number and percentages. The Mann-Whitney test was used for comparisons between two independent variables, while the Wilcoxon test was used to compare independent related variables. Analysis of SVR12 was performed on an intention-to-treat basis (including patients who were lost to follow-up and patients who failed TE measurement at baseline) and on a per-protocol basis (excluding patients lost to follow-up and failed baseline TE measurement). Any P-value lower than 0.05 was considered significant. showed a significant decrease from baseline to W4 (83 AE 26 to 12 AE 4, P < 0.001), to W8 (12 AE 4, P < 0.001) and to W12 (13 AE 13, P < 0.001). Due to the absence of severe fibrosis and liver cirrhosis, serum bilirubin and albumin concentrations were in the normal range before treatment start; however, bilirubin showed no change at W4
(0.84 AE 0.09 to 0.84 AE 0.12, P = 0.316), and a slight decrease from baseline at W8 (0.81 AE 0.12, P < 0.001) and W12 (0.79 AE 0.17,
| Haematological marker and renal function kinetics
Before the start of treatment, platelet count, haemoglobin and total leucocyte count (TLC) were within normal range. Platelet counts remained normal, haemoglobin showed at EOT a non-significant mean decrease in 0.13 AE 0.05 g/dL and TLC showed a nonsignificant mean decrease of 0.13 AE 0.51 9 10 3 /lL from baseline. Creatinine was within the normal range before treatment, and showed a mean decrease at W4 (0.54 AE 0.5, P < 0.001), at W8 (0.96 AE 0.12, P < 0.001), and at EOT (0.11 AE 0.11, P < 0.001) from baseline.
| Effectiveness of regimen and kinetics of virological markers
SVR12 in the intention-to-treat group was achieved in 147/154 patients (97%), while SVR12 in the per-protocol patients was 142/ 144 (99%) (Figure 2 ). 
| Per-protocol treatment relapsers
In the per-protocol group, both patients who relapsed were previously na€ ıve to anti-viral treatment. One of the two relapsers was a 12-year-old male, and had at baseline F0/F1, ALT and ASTconcentrations more than fourfold above the ULN at baseline, while the other patient was a 13-year-old male who had F0/F1, ALT and AST concentrations more than twofold above the ULN at baseline.
Relapse was associated with a rise in ALT and AST at W12, while the responders showed a continuous decrease in those markers.
Relapsers received treatment and were followed up.
| Safety and absence of serious adverse events
During the follow-up period, no treatment discontinuation or death was observed. In all patients, the most common adverse events were headache (29/144 (20%)) with no significant difference between na€ ıve and experienced groups. In the latter group, diarrhoea (44%, P < 0.001), pruritis (31%, P = 0.007) and skin rash (2%, P = 0.002) were higher than for the former group. In the na€ ıve group, one patient developed hyperbilirubinemia and anaemia, and one experienced patient showed anaemia with no associated hyperbilirubinemia. All side effects disappeared after the end of treatment with resolution of the anaemia and hyperbilirubinemia (Table 2) .
| DISCUSSION
This is the first observational, open-labelled multicentre study to evaluate the efficacy of a 12-week ledipasvir plus sofosbuvir regimen in an adolescent group of patients with HCV genotype 4. This study showed that this regimen has a high rate of sustained virological response in this group of patients. The regimen was well tolerated, with no discontinuation or death being reported. Most importantly, adverse events were minimal. This study also described an improvement in ALT and AST kinetics and virological markers in this group during treatment and until SVR12. We also evaluated the effect of prior treatment (na€ ıve/experienced), and found no significant difference in response. Although patients with significant fibrosis and liver cirrhosis were absent from this study, the use of transient elastography allowed classification into two groups; one with no or mild fibrosis (F0/F1) and another with F2, and no significant difference in SVR was observed with respect to treatment response. Interestingly, this study showed that the main source of infection in the study cohort was contact with infected patients, mostly in the family (68%) followed by perinatal infection (19%). This has been previously described. 18, 19 The decrease in the ALT and AST was previously described as the very first response to direct-acting anti-viral regimens. HCV RNA negative at W4, and 95% had undetectable HCV RNA W8 on this regimen. SVR12 was 99% in adolescent patients (perprotocol analysis), which is higher than previously described results in adults with genotypes 1, 2 and 3, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] and similar to recently published data in adolescents with genotypes 1, 2 and 3. 9, 16 The SVR was 100% in the experienced patients and also in patients with significant fibrosis (F2), and 98% in patients with no/mild fibrosis (F0/ F1). SVR12 was 97% in the intention-to-treat analysis. Relapse was only detected in two na€ ıve male adolescents with no-mild fibrosis.
Our study showed that this regimen was tolerated with minimal side effects, mainly headache, pruritis, fatigue, rash and diarrhoea, which were mainly described in experienced patients. This is in line with results of other studies performed in genotype 1 adolescents, 16 as well as in genotypes 2 and 3 9 and similar to those results in adult studies. 25, 26, 31 The major side effects were headache, pruritis and diarrhoea and there were no serious side effects that lead to treatment discontinuation. HB, haemoglobin; PLT, platelets; ALT, alanine aminotransferase; INR, international normalisation ratio; ULN, upper limit of normal; g/dL, gram/deciliter; lL, microliter; lmol/L, micromole/liter. P-value <0.05 is considered significant.
